Helius Bets $167M on Solana’s 7% Yields Over Bitcoin’s Dormant Reserves

Helius Medical Technologies, Inc. (NASDAQ: HSDT) has allocated $167 million toward the acquisition of Solana (SOL) tokens, marking a significant step in its digital asset treasury strategy. The company now holds over 760,190 SOL, with an average cost basis of $231 per token, as part of a broader initiative to position SOL as its primary reserve asset. The investment follows an oversubscribed $500 million private placement in public equity (PIPE) offering, which includes $750 million in stapled warrants, potentially scaling the total capital to $1.25 billionHelius (NASDAQ:HSDT) Begins Purchases of SOL, the Native Asset of Solana Blockchain^[1]. Proceeds will be directed toward open-market purchases of SOL and the development of a long-term treasury strategy focused on staking and DeFi opportunitiesSolana DAT SZN: Helius Medical Technologies Raises $500M^[2].

The funding round was led by Pantera Capital and Summer Capital, with participation from institutional investors such as Big Brain Holdings, FalconX, and Animoca BrandsHelius Medical Tech Jumps on Funding to Launch Solana Treasury^[3]. Pantera Capital, a key strategic partner, emphasized Solana’s status as the “most commercially viable blockchain” and highlighted its 7% native staking yield as a key advantage over non-yield-bearing assets like BitcoinHelius Medical Bets Big on Solana with $500 Million Investment^[4]. Helius Medical’s leadership, including Executive Chairman Joseph Chee (formerly of UBS) and Board Observer Cosmo Jiang (Pantera Capital), aims to leverage Solana’s high transaction throughput (3,500 transactions per second) and its 3.7 million daily active wallets to generate compounding returnsHelius Medical Raises $500M for Solana Treasury Plan^[5].

Solana’s financial productivity and infrastructure have attracted institutional interest, with Helius joining other firms like Forward Industries and DeFi Development Corp. in building large-scale Solana treasuries. Forward Industries, for example, recently acquired 6.82 million SOL at $232 per token, totaling $1.58 billion. Analysts note that Solana’s total value locked (TVL) in DeFi now exceeds $13 billion, second only to Ethereum, and that institutional allocations are driving ecosystem growth. Helius plans to gradually scale its SOL holdings over 12–24 months while maintaining a conservative risk profile and prioritizing transparency through regular reporting.

The move reflects a broader trend of public companies adopting digital asset treasuries to capitalize on blockchain yields. Helius’s stock surged over 140% following the announcement, mirroring similar gains seen by firms like BitMine after their crypto-focused strategies. However, the strategy carries risks, including regulatory uncertainty and market volatility. The company disclosed that forward-looking statements are subject to risks such as regulatory changes and fluctuating SOL prices.

Helius Medical’s initiative aligns with Pantera Capital’s broader vision for Solana as the “foundation of a new financial system.” The firm’s existing $1.1 billion Solana position underscores its conviction in the blockchain’s scalability and cost efficiency. With over $335 million in cash reserves, Helius aims to balance its neurotech operations with strategic digital asset holdings, positioning itself as a key institutional participant in the Solana ecosystem.